R
Rebecca Kruse-Jarres
Researcher at University of Washington
Publications - 87
Citations - 3093
Rebecca Kruse-Jarres is an academic researcher from University of Washington. The author has contributed to research in topics: Emicizumab & Haemophilia A. The author has an hindex of 23, co-authored 76 publications receiving 2143 citations. Previous affiliations of Rebecca Kruse-Jarres include Tulane University.
Papers
More filters
Journal ArticleDOI
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg,Johnny Mahlangu,Benjamin Kim,Christophe Schmitt,Michael U. Callaghan,Guy Young,Elena Santagostino,Rebecca Kruse-Jarres,Claude Negrier,Craig M. Kessler,Nancy Valente,Elina Asikanius,Gallia G. Levy,Jerzy Windyga,Midori Shima +14 more
TL;DR: Empicizumab prophylaxis was associated with a significantly lower rate of bleeding events than no proPHylaxis among participants with hemophilia A with inhibitors and resulted in a bleeding rate that was significantly lower by 79% than the rate with previous bypassing‐agent prophylum.
Journal ArticleDOI
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Johnny Mahlangu,Johannes Oldenburg,Ido Paz-Priel,Claude Negrier,Markus Niggli,M Elisa Mancuso,M Elisa Mancuso,Christophe Schmitt,Víctor Jiménez-Yuste,Christine L. Kempton,Christophe Dhalluin,Michael U. Callaghan,Willem Bujan,Midori Shima,Joanne I. Adamkewicz,Elina Asikanius,Gallia G. Levy,Rebecca Kruse-Jarres +17 more
TL;DR: Empicizumab prophylaxis administered subcutaneously once weekly or every 2 weeks led to a significantly lower bleeding rate than no proPHylaxis among persons with hemophilia A without inhibitors; more than half of the participants who received prophYLaxis had no treated bleeding events.
Journal ArticleDOI
Acquired hemophilia A: Updated review of evidence and treatment guidance.
Rebecca Kruse-Jarres,Christine L. Kempton,Francesco Baudo,Peter William Collins,Paul Knoebl,Cindy A. Leissinger,Andreas Tiede,Craig M. Kessler +7 more
TL;DR: Acquired hemophilia A is a rare disease resulting from autoantibodies against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and severe.
Journal ArticleDOI
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Guy Young,Ri Liesner,Tiffany Chang,Robert F. Sidonio,Johannes Oldenburg,Víctor Jiménez-Yuste,Johnny Mahlangu,Rebecca Kruse-Jarres,Michael Wang,Marianne Uguen,Michelle Y. Doral,Lilyan Wright,Christophe Schmitt,Gallia G. Levy,Midori Shima,Maria Elisa Mancuso +15 more
TL;DR: Emicizumab prophylaxis has been shown to be a highly effective novel medication for children with hemophilia A and inhibitors and two of 88 participants developed antidrug antibodies (ADAs) with neutralizing potential, ie, associated with decreased emicIZumab plasma concentrations.
Journal ArticleDOI
Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
Rebecca Kruse-Jarres,Jean St-Louis,Anne Greist,Amy D. Shapiro,Hedy Smith,Pratima Chowdary,A. Drebes,Edward D. Gomperts,C. Bourgeois,Min Mo,Aaron Novack,Heinrich D. Farin,Bruce M. Ewenstein +12 more
TL;DR: The ability to safely and effectively titrate dosing based on FVIII activity levels in this study demonstrates that OBI‐1 fulfils the unmet medical need to monitor the key coagulation parameter in AHA patients.